Feed Category: Weight Loss Index

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates,…

— Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) — —…

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

The stock rally followed news of a planned study combining the Allurion Program with GLP-1 therapies.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.

NATICK, Mass., January 24, 2025–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered…

There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining…

Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.

As the U.S. stock market continues its upward momentum, with the S&P 500 reaching a record closing high, investor optimism is buoyed by strong corporate…

NATICK, Mass., January 23, 2025–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate…